Table 5. Multivariable logistic regression by time to initiation of adjuvant endocrine therapy among women diagnosed with stages I–III hormone receptor-positive breast cancer.
| 0–3 Months | 0–6 Months | 0–9 Months | ||||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| AOR | 95 % CIa | AOR | 95 % CIa | AOR | 95 % CIa | |
| Initiate any hormonal therapya | ||||||
| Race/ethnicity | ||||||
| Non-Hispanic white | 1 | 1 | 1 | |||
| Non-Hispanic black | 0.78 | (0.65–0.94) | 0.85 | (0.72–1.00) | 0.92 | (0.78–1.10) |
| Hispanic (Mexican) | 1.24 | (0.84–1.84) | 1.18 | (0.82–1.69) | 1.56 | (1.05–2.32) |
| Hispanic (South/Central) | 1.28 | (0.79–2.07) | 0.97 | (0.62–1.51) | 0.97 | (0.61–1.54) |
| Hispanic (other/unknown) | 1.04 | (0.83–1.30) | 1.10 | (0.99–1.34) | 1.10 | (0.89–1.36) |
| Asian | 1.44 | (1.18–1.75) | 1.23 | (1.02–1.48) | 1.25 | (1.03–1.52) |
| Initiate tamoxifen therapya | ||||||
| Race/ethnicity | ||||||
| Non-Hispanic white | 1 | 1 | 1 | |||
| Non-Hispanic black | 0.77 | (0.55–1.08) | 0.67 | (0.50–0.90) | 0.72 | (0.55–0.93) |
| Hispanic (Mexican) | 0.59 | (0.21–1.62) | 0.27 | (0.10–0.74) | 0.28 | (0.12–0.70) |
| Hispanic (South/Central) | 0.70 | (0.22–2.23) | 0.68 | (0.29–1.57) | 0.79 | (0.38–1.65) |
| Hispanic (other/unknown) | 0.71 | (0.43–1.18) | 0.97 | (0.70–1.35) | 0.98 | (0.72–1.32) |
| Asian | 1.02 | (0.69–1.50) | 0.86 | (0.64–1.17) | 0.86 | (0.64–1.14) |
| Initiate AI therapya | ||||||
| Race/ethnicity | ||||||
| Non-Hispanic white | 1 | 1 | 1 | |||
| Non-Hispanic black | 0.83 | (0.68–1.00) | 0.98 | (0.84–1.15) | 1.07 | (0.91–1.25) |
| Hispanic (Mexican) | 1.43 | (0.95–2.14) | 1.57 | (1.11–2.23) | 2.11 | (1.45–3.07) |
| Hispanic (South/Central) | 1.43 | (0.87–2.36) | 1.10 | (0.71–1.70) | 1.07 | (0.69–1.66) |
| Hispanic (other/unknown) | 1.14 | (0.90–1.45) | 1.11 | (0.91–1.35) | 1.11 | (0.91–1.35) |
| Asian | 1.50 | (1.22–1.84) | 1.29 | (1.08–1.54) | 1.29 | (1.08–1.55) |
a
Adjusted odds ratio (AOR) controlled for all other socio-demographic and tumor characteristics listed in Table 1